Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Declines By 46.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totaling 120,361 shares, a drop of 46.4% from the June 15th total of 224,716 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 1,909,636 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, June 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Avalon GloboCare has an average rating of “Sell”.

Avalon GloboCare Stock Performance

Shares of NASDAQ:ALBT opened at $0.27 on Thursday. The company has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.61. The company has a market capitalization of $3.96 million, a P/E ratio of -0.08 and a beta of -0.03. Avalon GloboCare has a 52-week low of $0.21 and a 52-week high of $4.74.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.